Nykode Competitors

Stocks . Norway . 
Stock . Nykode Therapeutics ASA
NYKD Stock   2.61  0.03  1.16%   
Nykode Therapeutics ASA competes with Golden Energy, Nidaros Sparebank, BW Offshore, Sparebank, and Arcticzymes Technologies; as well as few others. Analyzing Nykode Therapeutics competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Nykode Therapeutics to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Nykode Therapeutics competition on your existing holdings.
  
Specify up to 10 symbols:

Nykode Therapeutics Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Nykode Therapeutics and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Nykode and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Nykode Therapeutics ASA does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
MING
+ 0.86
BWO
BWO
+ 0.8
NISB
AZT
+ 0.75
NISB
MING
+ 0.7
NISB
GRONG
+ 0.63
NISB
GRONG
+ 0.59
AZT
  
High negative correlations   
KRAB
- 0.41
MING
KRAB
- 0.24
BWO
MOBA
- 0.2
GEOS
KRAB
- 0.18
MOBA
KRAB
- 0.13
GEOS
AZT
- 0.0
GEOS

Risk-Adjusted Indicators

There is a big difference between Nykode Stock performing well and Nykode Therapeutics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Nykode Therapeutics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
All Fundamental Data

Nykode Therapeutics Competitive Analysis

The better you understand Nykode Therapeutics competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Nykode Therapeutics' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Nykode Therapeutics' competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
NYKD GEOS NISB BWO MOBA MING AZT KRAB GRONG
 1.16 
 2.61 
Nykode
 3.11 
 18.70 
Golden
 2.29 
 112.50 
Nidaros
 0.31 
 31.85 
BWO
 0.67 
 8.96 
Morrow
 0.39 
 181.50 
Sparebank
 0.53 
 18.80 
Arcticzymes
 2.22 
 8.80 
Kraft
 0.63 
 153.98 
Grong
Market Volatility
(90 Days Market Risk)
Very risky
Not too volatile
Very steady
Very steady
Not too volatile
Very steady
Not too volatile
Not too volatile
Very steady
Market Performance
(90 Days Performance)
Very Weak
Modest
OK
Good
Insignificant
Good
Good
Insignificant
Insignificant
Odds of Financial Distress
(Probability Of Bankruptcy)
Unknown
Above Average
Low
Low
Unknown
Below Average
Low
Low
Low
Current Valuation
(Equity Enterprise Value)
Over Valued
Over Valued
Over Valued
Under Valued
Under Valued
Under Valued
Under Valued
Over Valued
Under Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Strong Sell
Strong Sell
Strong Sell
Strong Hold
Hold
Strong Hold
Hold
Strong Sell
Hold
Current Ratio
0.17
N/A
0.58
N/A
14.94
N/A
N/A
Net Asset
470.62 M
4.3 B
3.01 B
223.31 B
284.11 M
2.88 B
7.91 B
Profit Margin
-0.48
0.23
0.0563
0.45
0.24
0.33
0.5
EBITDA
(27.3 M)
N/A
365.7 M
4.66 B
62.89 M
N/A
N/A
Operating Margin
-0.15
0.29
0.16
0.59
0.27
0.45
0.54
Current Valuation
470.41 M
N/A
14.06 B
32.72 B
3.42 B
N/A
722.47 M
Price To Book
0.65
0.23
0.54
0.66
13.01
0.96
0.58
Current Asset
N/A
N/A
524 M
30.02 B
N/A
N/A
N/A
Five Year Return
N/A
N/A
10.45
4.91
N/A
N/A
N/A
Retained Earnings
N/A
N/A
N/A
8.2 B
N/A
N/A
N/A
Beta
0.73
-0.0352
1.99
0.91
1.13
1.03
0.14
Number Of Employees
3
23
1.4 K
1.43 K
60
4
63
Shares Outstanding
53.77 M
1.13 M
180.82 M
129.78 M
50.57 M
42 M
3.97 M
Cash Flow From Operations
5.81 M
(109.95 M)
510.2 M
(6.84 B)
74.97 M
58.99 M
(220.29 M)
Annual Yield
N/A
0.0533
0.0515
0.0504
N/A
0.0278
0.05
Total Debt
57.41 M
50.09 M
815.4 M
42.13 B
14.47 M
4.39 M
1.42 B
Return On Equity
-0.68
0.0402
0.0385
0.12
0.13
0.12
0.14
Z Score
0.6
1.2
3.6
N/A
88.2
51.0
N/A
Return On Asset
-0.0239
0.005
0.0247
0.0132
0.0756
0.0141
0.0167
Book Value Per Share
2.16
473.41
4.89
185.72
5.64
9.53
278.93
Current Liabilities
N/A
N/A
648 M
79.56 B
N/A
N/A
N/A
Total Asset
470.62 M
4.3 B
3.01 B
223.31 B
284.11 M
2.88 B
7.91 B
Debt To Equity
1.68
N/A
100.1
N/A
0.08
N/A
N/A
Target Price
N/A
117.0
44.73
148.2
N/A
N/A
162.0
Last Dividend Paid
N/A
5.86
0.14
6.5
N/A
N/A
9.0
Shares Owned By Institutions
33.1
N/A
20.38
36.17
20.32
N/A
6.33
Market Capitalization
93.84 M
124.14 M
4.97 B
16.74 B
2.13 B
373.8 M
635.6 M
Price To Earning
N/A
17.11
212.6
13.31
45.11
14.86
9.76
Price To Earnings To Growth
N/A
N/A
-0.46
0.72
N/A
N/A
N/A
Price To Sales
0.57
1.37
5.77
2.44
25.59
2.64
2.3
Net Income
(63.16 M)
27.75 M
62.6 M
2.65 B
46.38 M
46.24 M
85.87 M
Earnings Per Share
-1.38
0.88
1.13
11.44
0.9
1.02
16.16
Shares Owned By Insiders
40.6
52.13
52.85
6.87
34.44
51.27
38.1
Revenue
71.19 M
94.99 M
829.3 M
5.32 B
127.97 M
130.9 M
218.17 M
Working Capital
N/A
N/A
(124 M)
(49.55 B)
N/A
N/A
N/A
Cash And Equivalents
791 K
554.07 M
266.7 M
45.74 B
200.42 M
59.4 M
892.5 M
Cash Per Share
N/A
492.07
0.96
353.74
3.52
1.41
300.25
Gross Profit
(7.41 M)
99.28 M
452.5 M
5.95 B
132.48 M
139.41 M
212.51 M
Day Typical Price
2.6
19.17
112.5
31.98
9.0
181.21
18.77
8.83
154.31
Accumulation Distribution
28781.47
6494.72
N/A
390.05
1708.62
1822.1
456.15
235.85
0.55
Market Facilitation Index
N/A
1.0E-4
N/A
0.0
0.0
0.0
0.0
0.0
0.0113
Daily Balance Of Power
0.2143
(0.23)
9.2 T
(0.17)
0.3
0.3723
(0.24)
(2.00)
(1.00)
Period Momentum Indicator
0.03
(0.60)
2.52
(0.10)
0.06
0.7
(0.10)
(0.20)
(0.98)
Rate Of Daily Change
1.01
0.97
1.02
1.0
1.01
1.0
0.99
0.98
0.99
Day Median Price
2.59
19.4
112.5
32.05
9.02
181.06
18.75
8.85
154.47
Price Action Indicator
0.035
(1.00)
1.26
(0.25)
(0.03)
0.79
N/A
(0.15)
(0.98)
Coefficient Of Variation
1817.35
(1,495)
660.57
794.44
653.45
508.93
652.6
5413.32
2154.15
Mean Deviation
3.23
2.4
0.7137
1.53
1.61
0.662
2.27
1.14
0.5362
Jensen Alpha
0.2212
(0.29)
0.1752
0.2438
0.3394
0.1607
0.574
0.0241
0.0344
Total Risk Alpha
0.2495
(0.26)
0.1842
0.2562
0.3536
0.1656
0.5974
0.0371
0.041
Sortino Ratio
0.0607
N/A
0.1142
0.1492
0.1986
0.1876
0.2954
0.0112
0.0317
Downside Variance
13.95
N/A
2.51
2.76
2.99
0.7711
3.82
6.99
1.55
Standard Deviation
4.21
4.15
1.23
2.01
2.28
0.8645
3.8
1.88
0.962
Kurtosis
1.18
17.9
6.16
0.0851
2.3
0.5117
15.2
2.08
4.45
Potential Upside
7.31
5.07
2.29
4.26
4.51
1.45
4.35
3.49
1.67
Treynor Ratio
(1.85)
0.3388
(0.94)
1.41
1.99
0.9556
1.71
(0.19)
(0.71)
Maximum Drawdown
21.3
27.18
8.36
7.88
12.82
4.21
25.72
10.32
4.98
Variance
17.74
17.21
1.51
4.04
5.19
0.7474
14.45
3.54
0.9255
Market Risk Adjusted Performance
(1.84)
0.3488
(0.93)
1.42
2.0
0.9656
1.72
(0.18)
(0.70)
Risk Adjusted Performance
0.0487
(0.04)
0.1152
0.0988
0.1192
0.1458
0.1206
0.0197
0.0365
Skewness
0.8049
(3.08)
1.54
0.568
1.06
(0.31)
3.28
(0.0006)
(0.46)
Semi Deviation
3.47
N/A
0.55
1.39
1.35
0.6146
1.58
1.55
0.73
Information Ratio
0.0538
(0.07)
0.1472
0.1233
0.1508
0.1905
0.1519
0.0157
0.0411
Value At Risk
(5.65)
(6.01)
(1.68)
(2.97)
(2.24)
(1.60)
(3.18)
(3.37)
(1.32)
Expected Short fall
(3.67)
N/A
(1.74)
(1.93)
(2.10)
(0.73)
(3.22)
(2.01)
(0.97)
Downside Deviation
3.73
N/A
1.58
1.66
1.73
0.8781
1.95
2.64
1.25
Semi Variance
12.07
N/A
0.3025
1.92
1.82
0.3777
2.49
2.4
0.5329

Nykode Therapeutics Competition Performance Charts

Five steps to successful analysis of Nykode Therapeutics Competition

Nykode Therapeutics' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Nykode Therapeutics ASA in relation to its competition. Nykode Therapeutics' competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Nykode Therapeutics in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Nykode Therapeutics' competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Nykode Therapeutics ASA, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Nykode Therapeutics position

In addition to having Nykode Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Broad Market ETFs Thematic Idea Now

Broad Market ETFs
Broad Market ETFs Theme
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Broad Market ETFs theme has 71 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Broad Market ETFs Theme or any other thematic opportunities.
View All  Next Launch
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY